APA-Zitierstil (7. Ausg.)

Schnaiter, A. B., Paschka, P., Rossi, M., Zenz, T., Bühler, A., Winkler, D., . . . Stilgenbauer, S. (2013). NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: Results from the CLL2H trial of the GCLLSG. Blood, 122(7), . https://doi.org/10.1182/blood-2013-03-488197

Chicago-Zitierstil (17. Ausg.)

Schnaiter, Andrea Barbara, et al. "NOTCH1, SF3B1, and TP53 Mutations in Fludarabine-refractory CLL Patients Treated with Alemtuzumab: Results from the CLL2H Trial of the GCLLSG." Blood 122, no. 7 (2013). https://doi.org/10.1182/blood-2013-03-488197.

MLA-Zitierstil (9. Ausg.)

Schnaiter, Andrea Barbara, et al. "NOTCH1, SF3B1, and TP53 Mutations in Fludarabine-refractory CLL Patients Treated with Alemtuzumab: Results from the CLL2H Trial of the GCLLSG." Blood, vol. 122, no. 7, 2013, https://doi.org/10.1182/blood-2013-03-488197.